USD 1.13
↓ -0.12 (-9.6%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ZVSA | -9.6 | -28.5 | -50.9 | -62.6 | -77.1 | -96.1 | -100.0 | -100.0 | -100.0 | -100.0 |
| S&P 500 | -0.6 | -0.5 | 2.3 | 7.3 | 12.1 | 32.1 | 27.0 | 90.7 | 191.4 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ZVSA |
| name | ZyVersa Therapeutics, Inc. |
| price | 1.13 |
| changes percentage | -9.60 |
| change | -0.12 |
| day low | 1.10 |
| day high | 1.22 |
| year high | 42.35 |
| year low | 1.10 |
| market cap | 1213841 |
| price avg 50 | 2.17 |
| price avg 200 | 4.61 |
| exchange | NASDAQ |
| volume | 252891 |
| avg volume | 1197493 |
| open | 1.22 |
| previous close | 1.25 |
| eps | 1,163.36 |
| pe | 0 |
| earnings announcement | 2024-11-14T12:00:00.000+0000 |
| shares outstanding | 1074196 |
| timestamp | 2024-11-14 21:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001859007 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -10400 | -10400 | 0.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 3207573 | 5407859 | -40.69 |
| operating expenses | 14410374 | 13013064 | 10.74 |
| interest income | 0 | 427.54 | -100.00 |
| interest expense | -457000 | 427542 | -206.89 |
| ebitda | -107743376 | -11671732 | -823.11 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -14420774 | -13013064 | -10.82 |
| operating income ratio | 0 | 0 | NaN |
| net income | -98297946 | -759097607 | 87.05 |
| net income ratio | 0 | 0 | NaN |
| eps | -1089.67 | -2925.42 | 62.75 |
Research and Development (R&D) Expenses: R&D Expenses decreased to 3 million in 2023 from 5 million in 2022 representing a change of -40.69%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 14 million in 2023 from 13 million in 2022 representing a change of 10.74%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -108 million in 2023 from -12 million in 2022 representing a change of -823.11%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income increased to -14 million in 2023 from -13 million in 2022 representing a change of -10.82%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -98 million in 2023 from -759 million in 2022 representing a change of 87.05%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -1089.67 in 2023 from -1089.67 in 2022 representing a change of 62.75%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001859007 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -2600 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 436043000 | 709049 | 61,396.88 |
| operating expenses | 2269621000 | 2751378 | 82,390.34 |
| interest income | 0 | 0 | NaN |
| interest expense | 131635000 | 58 | 226,956,796.55 |
| ebitda | -2269621000 | -2751378 | -82,390.34 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -2269621000 | -2753978 | -82,312.46 |
| operating income ratio | 0 | 0 | NaN |
| net income | -2401256000 | -2763743 | -86,784.20 |
| net income ratio | 0 | 0 | NaN |
| eps | -242.95 | -3.31 | -7,239.88 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 2,270 million in 2024Q3 from 3 million in 2024Q2 representing a change of 82390.34%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Research and Development (R&D) Expenses: R&D Expenses decreased to 436 million in 2024Q3 from 1 million in 2024Q2 representing a change of 61396.88%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -2,270 million in 2024Q3 from -3 million in 2024Q2 representing a change of -82390.34%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -2,270 million in 2024Q3 from -3 million in 2024Q2 representing a change of -82312.46%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -2,401 million in 2024Q3 from -3 million in 2024Q2 representing a change of -86784.2%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -242.95 in 2024Q3 from -242.95 in 2024Q2 representing a change of -7239.88%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001859007 | |||
| total assets | 22114284 | 118506271 | -81.34 |
| total liabilities | 11039686 | 18511943 | -40.36 |
| total equity | 11074598 | 99994328 | -88.92 |
| cash and cash equivalents | 3137674 | 5902199 | -46.84 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 3353133 | 6362546 | -47.30 |
| total non current assets | 18761151 | 112143725 | -83.27 |
| total current liabilities | 10194772 | 8187960 | 24.51 |
| total non current liabilities | 844914 | 10323983 | -91.82 |
| common stock | 405 | 902 | -55.10 |
| retained earnings | -103219124 | -4921178 | -1,997.45 |
| total debt | 8656 | 108756 | -92.04 |
Total Assets: Total Assets decreased to 22 million in 2023 from 119 million in 2022 representing a change of -81.34%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 11 million in 2023 from 100 million in 2022 representing a change of -88.92%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 3 million in 2023 from 6 million in 2022 representing a change of -46.84%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 3 million in 2023 from 6 million in 2022 representing a change of -47.3%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 10 million in 2023 from 8 million in 2022 representing a change of 24.51%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 0 in 2023 from 0 in 2022 representing a change of -55.1%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -103 million in 2023 from -5 million in 2022 representing a change of -1997.45%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 11 million in 2023 from 19 million in 2022 representing a change of -40.36%. This indicates a decrease in overall liabilities.
Total Debt: Total Debt decreased to 0 million in 2023 from 0 million in 2022 representing a change of -92.04%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001859007 | |||
| total assets | 19423924000 | 19469504 | 99,665.89 |
| total liabilities | 12396624000 | 10849449 | 114,160.40 |
| total equity | 7027300000 | 8620055 | 81,422.68 |
| cash and cash equivalents | 122921000 | 119486 | 102,774.81 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 390415000 | 641392 | 60,769.95 |
| total non current assets | 19033509000 | 18828112 | 100,990.91 |
| total current liabilities | 11542003000 | 9994828 | 115,379.76 |
| total non current liabilities | 854621000 | 854620 | 99,900.12 |
| common stock | 214000 | 83 | 257,731.33 |
| retained earnings | -111210860000 | -108809604 | -102,106.84 |
| total debt | 0 | 0 | NaN |
Total Assets: Total Assets increased to 19,424 million in 2024Q3 from 19 million in 2024Q2 representing a change of 99665.89%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 7,027 million in 2024Q3 from 9 million in 2024Q2 representing a change of 81422.68%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 123 million in 2024Q3 from 0 million in 2024Q2 representing a change of 102774.81%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 390 million in 2024Q3 from 1 million in 2024Q2 representing a change of 60769.95%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 257731.33%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 12,397 million in 2024Q3 from 11 million in 2024Q2 representing a change of 114160.4%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 11,542 million in 2024Q3 from 10 million in 2024Q2 representing a change of 115379.76%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -111,211 million in 2024Q3 from -109 million in 2024Q2 representing a change of -102106.84%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001859007 | |||
| net change in cash | -2764525 | 370743 | -845.67 |
| operating cash flow | -8720819 | -1494641 | -483.47 |
| free cash flow | -8720820 | -1494641 | -483.47 |
| capital expenditure | -1 | 0 | NaN |
| depreciation and amortization | 10400 | 9868 | 5.39 |
| deferred income tax | -9479069 | -745050 | -1,172.27 |
| stock based compensation | 1192963 | 3524801 | -66.16 |
| accounts payables | 2405938 | 6617064 | -63.64 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -1 | 0 | NaN |
| net cash used for investing activites | 0 | 0 | NaN |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 18114193 | 1865384 | 871.07 |
| common stock repurchased | -10702779 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 5956294 | 1865.38 | 319,206.59 |
| cash at end of period | 3137674 | 699324 | 348.67 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 5902199 | 328581 | 1,696.27 |
Net Change in Cash: Net Change in Cash decreased to -3 million in 2023 from 0 million in 2022 representing a change of -845.67%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -9 million in 2023 from -1 million in 2022 representing a change of -483.47%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -9 million in 2023 from -1 million in 2022 representing a change of -483.47%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2023 from 0 million in 2022 representing a change of nan%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 1 million in 2023 from 4 million in 2022 representing a change of -66.16%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 2 million in 2023 from 7 million in 2022 representing a change of -63.64%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001859007 | |||
| operating cash flow | -3078600000 | -1914090 | -160,738.83 |
| free cash flow | -3078600000 | -1914090 | -160,738.83 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 6933000 | 2600 | 266,553.85 |
| deferred income tax | 9707000 | 9707 | 99,900.00 |
| stock based compensation | 257441000 | 160664 | 160,135.65 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | 676178000 | 188760 | 358,121.02 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | 0 | 0 | NaN |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -316000000 | 79199000 | -498.99 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 2925171000 | 0 | NaN |
| net change in cash | 2984210000 | -1914090 | 156,007.51 |
| cash at end of period | 122921000 | 119486 | 102,774.81 |
| cash at beginning of period | -2861289000 | 2033576 | -140,802.34 |
Net Change in Cash: Net Change in Cash increased to 2,984 million in 2024Q3 from -2 million in 2024Q2 representing a change of 156007.51%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -3,079 million in 2024Q3 from -2 million in 2024Q2 representing a change of -160738.83%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -3,079 million in 2024Q3 from -2 million in 2024Q2 representing a change of -160738.83%. This indicates a decrease in cash generated after accounting for capital expenditures.
Deferred Income Tax: Deferred Income Tax increased to 10 million in 2024Q3 from 0 million in 2024Q2 representing a change of 99900.0%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 257 million in 2024Q3 from 0 million in 2024Q2 representing a change of 160135.65%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 676 million in 2024Q3 from 0 million in 2024Q2 representing a change of 358121.02%. This indicates that the company has increased its outstanding obligations to its suppliers.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -1008.15 | -2925.42 | 65.54 |
| operating cash flow per share | -89.44 | -5.76 | -1,452.78 |
| free cash flow per share | -89.44 | -5.76 | -1,452.79 |
| cash per share | 32.18 | 22.75 | 41.48 |
| book value per share | 113.58 | 385.36 | -70.53 |
| tangible book value per share | -77.67 | -46.2 | -68.14 |
| shareholders equity per share | 113.58 | 385.36 | -70.53 |
| interest debt per share | -4.69 | 2.07 | -326.78 |
| market cap | 877527 | 142443192.85 | -99.38 |
| enterprise value | -2251491 | 136649749.85 | -101.65 |
| pe ratio | -0.01 | -0.19 | 95.24 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -0.1 | -95.3 | 99.89 |
| pfcf ratio | -0.1 | -95.3 | 99.89 |
| pb ratio | 0.08 | 1.42 | -94.44 |
| ptb ratio | 0.08 | 1.42 | -94.44 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | 0.02 | -11.71 | 100.18 |
| ev to operating cash flow | 0.26 | -91.43 | 100.28 |
| ev to free cash flow | 0.26 | -91.43 | 100.28 |
| earnings yield | -112.02 | -5.33 | -2,001.98 |
| free cash flow yield | -9.94 | -0.01 | -94,611.27 |
| debt to equity | 0 | 0.0 | -100.00 |
| debt to assets | 0 | 0.0 | -100.00 |
| net debt to ebitda | 0.03 | 0.5 | -94.15 |
| current ratio | 0.33 | 0.78 | -57.67 |
| interest coverage | 31.56 | -30.44 | 203.67 |
| income quality | 0.09 | 0.11 | -16.62 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.84 | 0.94 | -10.76 |
| capex to operating cash flow | -0.0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 1605.13 | 5036.38 | -68.13 |
| roic | -1.19 | -7.02 | 83.09 |
| return on tangible assets | -28.36 | -116.34 | 75.62 |
| graham net net | -81.04 | -48.6 | -66.77 |
| working capital | -6841639 | -1825414 | -274.80 |
| tangible asset value | -7573305 | -11987034 | 36.82 |
| net current asset value | -7686553 | -12149397 | 36.73 |
| invested capital | 11821036 | 110271652 | -89.28 |
| average receivables | 0 | 0 | NaN |
| average payables | 7228614 | 4012872.5 | 80.14 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 295916.13 | 211476.96 | 39.93 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.0 | 0.0 | -28.53 |
| inventory turnover | 0 | 0 | NaN |
| roe | -8.88 | -7.59 | -16.92 |
| capex per share | 0.0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -8.88 on 2023-12-31 from -7.59 on 2022-12-31, representing a change of -16.92%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 0.33 on 2023-12-31 from 0.78 on 2022-12-31, representing a change of -57.67%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.01 on 2023-12-31 from -0.19 on 2022-12-31, representing a change of 95.24%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2023-12-31 from 0.00 on 2022-12-31, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ZVSA | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -242.95 | -3.31 | -7,239.39 |
| operating cash flow per share | -311.48 | -2.29 | -13,486.58 |
| free cash flow per share | -311.48 | -2.29 | -13,486.58 |
| cash per share | 12.44 | 0.14 | 8,590.17 |
| book value per share | 710.99 | 10.32 | 6,786.49 |
| tangible book value per share | 710.99 | -12.01 | 6,019.70 |
| shareholders equity per share | 710.99 | 10.32 | 6,786.49 |
| interest debt per share | 13.32 | 0.0 | 19,171,686.23 |
| market cap | 23721072 | 3014043.15 | 687.02 |
| enterprise value | -99199928 | 2894557.15 | -3,527.12 |
| pe ratio | -0.0 | -0.27 | 99.09 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -0.01 | -1.57 | 99.51 |
| pfcf ratio | -0.01 | -1.57 | 99.51 |
| pb ratio | 0.0 | 0.35 | -99.03 |
| ptb ratio | 0.0 | 0.35 | -99.03 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | 0.04 | -1.05 | 104.15 |
| ev to operating cash flow | 0.03 | -1.51 | 102.13 |
| ev to free cash flow | 0.03 | -1.51 | 102.13 |
| earnings yield | -101.23 | -0.92 | -10,939.67 |
| free cash flow yield | -129.78 | -0.64 | -20,336.48 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 0.05 | 0.04 | 24.71 |
| current ratio | 0.03 | 0.06 | -47.29 |
| interest coverage | -17.24 | -47482.38 | 99.96 |
| income quality | 0.69 | 0.69 | -0.06 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0.96 | -100.00 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 1971.43 | 27.73 | 7,009.33 |
| roic | -0.32 | -0.32 | -0.74 |
| return on tangible assets | -0.12 | -3.36 | 96.32 |
| graham net net | -1241.8 | -12.85 | -9,562.66 |
| working capital | -11151588000 | -9353436 | -119,124.51 |
| tangible asset value | 7027300000 | -10027848 | 70,177.85 |
| net current asset value | -12006209000 | -10208057 | -117,515.03 |
| invested capital | -11151588000 | 9296200 | -120,058.56 |
| average receivables | 0 | 0 | NaN |
| average payables | 4646473753 | 8222126 | 56,411.83 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 287879.05 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.0 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.34 | -0.32 | -6.58 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -0.34 on 2024-09-30 Q3 from -0.32 on 2024-06-30 Q2, representing a change of -6.58%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 0.03 on 2024-09-30 Q3 from 0.06 on 2024-06-30 Q2, representing a change of -47.29%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.00 on 2024-09-30 Q3 from -0.27 on 2024-06-30 Q2, representing a change of 99.09%. Indicating an increase in the relative valuation of the company's stock.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-14 08:10:00
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025. New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.
Sentiment: Negative
Publish Date: 2024-11-05 07:00:00
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells. Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes.
Sentiment: Negative
Publish Date: 2024-10-29 07:57:00
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders. With weight loss, less inflammation is expected, but adipose tissue inflammation can persist long after weight loss.
Sentiment: Negative
Publish Date: 2024-10-22 07:57:00
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases The newly published data show that obesity leads to progressive brain inflammation in a mouse model, and that the proinflammatory processes worsen with prolonged obesity and with increased age This research supports our selection of obesity with associated comorbidities as the lead indication for Inflammasome ASC Inhibitor IC 100 IC 100 inhibits intra- and extracellular ASC and specks associated with multiple types of inflammasomes to attenuate damaging neurologic and systemic inflammation WESTON, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in the peer-reviewed journal, Aging Cell, demonstrating that obesity in older adults or prolonged duration of obesity in the younger population resulted in inflammation and suppression of neurotrophic/neuroprotective factors in the brain, indicating that age and duration of obesity are critical risk factors for neurodegenerative diseases.
Sentiment: Negative
Publish Date: 2024-10-17 07:50:00
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
Sentiment: Negative
Publish Date: 2024-10-15 07:50:00
WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that Stephen C.
Sentiment: Positive
Publish Date: 2024-10-07 07:55:00
New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University of Miami Miller School of Medicine who have provided ongoing scientific advisory support for IC 100 since its license. WESTON, Fla.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
